← Back to Search

Radiotracer

PET Imaging for Fatty Liver Disease

Phase < 1

Waitlist Available

Led By Guobao Wang, PhD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants >=18 years age

Be older than 18 years old

Must not have

History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease

Significant history of major skull concussion or repetitive head trauma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is looking at how chronic liver diseases, like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), may affect Alzheimer's Disease and related dementias (ADRD) through

Who is the study for?

This trial is for adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) who may also be experiencing cognitive decline. The study aims to explore the connection between liver inflammation and brain health using advanced PET imaging techniques.

What is being tested?

The trial is testing a new PET imaging method using two tracers, 18F-FDG and 18F-DPA-714, to assess inflammation in both the liver and brain of patients with MASLD-related cognitive issues. This could help understand how liver disease might affect Alzheimer's Disease.

What are the potential side effects?

Potential side effects are related to PET scanning, which may include discomfort from injection of the tracers, allergic reactions, or exposure to radiation. However, these risks are generally considered low.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of liver issues, but not due to non-alcoholic fatty liver disease.

Select...

I have had a severe concussion or many head injuries.

Select...

I am currently taking blood thinners.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

results of 18F-FDG scans compared with results of DPA-714 scans

Secondary study objectives

Compare levels of neuroinflammation detected using FDG and DPA-714 scans to the levels of liver inflammation determined through biopsies

Other study objectives

results from PET scans compared with Brain MRI and neurocognitive testing

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: ImagingExperimental Treatment2 Interventions

Participants will undergo positron emission tomography scans. One scan will be performed after administration of 18F-FDG while the other will be perfomred after administration of 18F-DPA-714.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

18F-FDG

2017

Completed Phase 4

~750

0 / 4Eligibility criteria met